^
Association details:
| Biomarker: | EGFR S768_D770dup |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Rybrevant (amivantamab-vmjw) (EGFR inhibitor, c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC
Published date:
08/12/2020
Excerpt:
...a 48-year-old patient with the EGFR S768_D770dup Exon20ins mutation achieved a partial response with a 38.9% tumor reduction (Fig. 7B). These patients were progression-free for 92 and 32 weeks, respectively, on amivantamab, with manageable toxicities.
DOI:
10.1158/2159-8290.CD-20-0116
Trial ID:
